Our Journey

Britannia Pharmaceuticals Ltd. has undergone a large growth in the past 30 years, and operates as the global specialty centre for Parkinson’s Disease in the STADA Network.

Read about journey from a small, family run business, to sharing products internationally.

1982

Britannia is founded

Britannia Pharmaceuticals Ltd. was founded as a small, family run business in 1982 in the United Kingdom.

1992

Apomorphine

The first apomorphine product was launched in the United Kingdom. This product came in the form of an apomorphine infusion.

2004

Expanding Therapy Areas

The Mental Health Business Unit (MHBU) was formed in the UK to support schizophrenic patients.

2007

Global Expansion with the STADA Group

Britannia Pharmaceuticals Ltd. joins the STADA Group, expanding our reach across the globe, and securing our legacy as the global Parkinson’s Disease centre of excellence with the group.

2014

Continued R&D

Research and Development investment accelerated.

2018

TOLEDO Study

The TOLEDO Study is published. This was the first prospective, double-blind, randomised, placebo-controlled, multicentre study of apomorphine subcutaneous infusion in patients with PD.

2020

Lobsor Pharmaceuticals

STADA acquired Lobsor Pharmaceuticals, bringing an infusion device to Britannia’s portfolio of treatments for Advanced Parkinson’s Disease.